Reverse engineering in medical applications

Introduction to reverse engineering in medical applications 

At Applus+ Laboratories, we position reverse engineering as a risk-controlled, standards-driven process. We apply accredited analytical methods to characterize materials, geometries, manufacturing processes, and functional performance of medical devices. This approach enables manufacturers to reconstruct design intent, evaluate equivalence, and generate objective technical evidence aligned with regulatory expectations. 

Reverse engineering plays a critical role in scenarios such as discontinued suppliers, incomplete design history files, product optimization, and competitive analysis. When executed under ISO 17025-accredited conditions, it becomes a defensible technical foundation rather than an exploratory exercise. 

Medical reverse engineering methods and technologies 

Reverse engineering in the medical sector requires a multidisciplinary methodology combining mechanical analysis, materials science, chemistry, and metrology. Each activity is mapped to recognized standards to ensure data integrity and regulatory relevance. 

Phases of reverse engineering 

The reverse engineering workflow is structured into sequential, traceable phases: 

1. Initial device assessment and teardown 
Devices are documented, disassembled, and classified by materials, subassemblies, and functional interfaces.  

2. Material identification and characterization is based on a multi-analytical approach combining thermal, chromatographic, spectroscopic, and microscopic techniques to identify both declared and undeclared compounds (polymers, additives, fillers). 
Bulk and advanced analyses such as Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), liquid chromatography (LC-MS) and gas chromatography (GC-MS and Py-GC-MS) enable detailed characterization of organic composition and polymer structure. 
Complementary techniques (SEM‑EDS, particle sizing) and metallic compositions confirmed using Inductively Coupled Plasma Mass Spectrometry (ICP-MS) assess inorganic content and morphology, ensuring a comprehensive and data‑driven understanding of material composition. 

3. Chemical and biological risk evaluation 
For patient‑contacting devices, extractables and leachables screening is performed in alignment with ISO 10993‑18, with toxicological risk assessment aligned with ISO 10993‑17. This phase is essential when reverse engineering enables equivalence claims or design changes. 

4. Functional and performance analysis 
Mechanical, electrical, or functional testing is conducted to benchmark performance characteristics. Methods are selected based on applicable ASTM or ISO device-specific standards. 

5. Technical documentation and data integration 
Results are consolidated into structured technical reports suitable for design history files, supplier qualification, or regulatory submissions, enabling demonstration of equivalence under EU MDR Annex XIV or FDA pathways. 

Technologies of reverse engineering 

Applus+ Laboratories deploys a comprehensive technology stack to enable medical reverse engineering: 

• DSC calorimeter for polymer intrinsic characteristics such as melting point, glass transition or cristallinity 
• TGA thermogravimetric analysis to quantitfy the amount of inorganic compound 
• FTIR spectroscopy for polymer identification and verification against USP <661> and ISO 10993 material requirements. 
• HPLC and GC-MS for chemical characterization of additives, residual monomers, and degradation products in accordance with ISO 10993-18. 

All analytical activities are performed within ISO 17025-accredited laboratories, ensuring traceability, repeatability, and defensible data. 

• ICP-MS and ICP-OES for trace metal analysis, impurity profiling, and degradation studies. 
• SEM and SEM-EDS for surface morphology, failure analysis, and elemental composition, particularly relevant for implants and coated devices. 

Applications of reverse engineering in medical devices 

Reverse engineering supports multiple high-value applications across the medical device lifecycle: 

• Legacy device reconstruction 

When original design data is incomplete or unavailable, reverse engineering enables manufacturers to rebuild technical knowledge while aligning with current regulatory requirements. 

• Competitive benchmarking and market intelligence 

Detailed analysis of competitor devices provides insight into material choices, manufacturing techniques, and design strategies without speculative assumptions. 

• Supplier change and remediation 

Reverse engineering establishes objective specifications when qualifying alternate suppliers or addressing component obsolescence. 

• Design optimization and cost reduction 

Understanding material formulations and manufacturing processes allows manufacturers to optimize performance, durability, and manufacturability while maintaining functional equivalence. 

• Regulatory equivalence and technical justification 

Data generated through reverse engineering enable equivalence claims, substantial equivalence arguments, and technical documentation under EU MDR and FDA frameworks. 

In each application, the value lies not only in the data collected, but in its regulatory relevance and technical defensibility. 

The future of reverse engineering in medical applications 

The future of reverse engineering in medical applications is defined by convergence: digitalization, advanced analytics, and regulatory rigor. Artificial intelligence-assisted image analysis, digital twins, and model-based engineering are expanding the depth and speed of reverse engineering activities. 

At the same time, regulatory authorities are increasing expectations for chemical characterization, biological risk assessment, and objective equivalence data. Reverse engineering will continue to evolve from a reactive tool into a proactive strategy embedded in product development, lifecycle management, and post-market surveillance. 

Manufacturers that integrate reverse engineering early—enabled by accredited laboratories and standardized methodologies—will be better positioned to manage risk, control costs, and accelerate innovation without compromising regulatory confidence.